DRC & Research News

This page shares the latest news in T1D research and DRC’s community.

Get the most recent diabetes research news, delivered straight to your inbox

Diabetes Research Connection Celebrates Achievements Amid Year-End Giving Campaign to Fund Type 1 Diabetes Research

Supported by corporate sponsorships, county grants, foundation awards, and a donation of $100,000 in matching funds, DRC pushes to fund more innovative research to find the cause, treatment, and cure for T1D

SAN DIEGO – December 16, 2021 – Diabetes Research Connection (DRC), a 501(c)(3) that funds research projects conducted by early-career researchers aimed at prevention, cure, and better care for those with Type 1 Diabetes (T1D), announces significant achievements in 2021 amid its year-end giving campaign. This year, DRC has been supported by corporate sponsorships, county grants, foundation awards, and a $100,000 dollar-for-dollar matching gift from an anonymous donor.

In 2021 alone, DRC will provide seed funding for 16 new T1D research projects, bringing the total to 48 innovative studies by early-career scientists awarded since its founding in 2012. DRC expects to support close to $2M in research by year-end, with six early-career scientists receiving DRC funding going on to secure $8.4M in additional funds for their T1D research.

“DRC is committed to providing seed funding for early-career scientists to demonstrate the viability of their peer-reviewed, innovative T1D research ideas. Data driven outcomes show proof of concept to enable our scientists to pursue follow-on funding, often yielding over $1 million,” shared DRC Co-Founder, David Winkler.

 Corporate partners and financial underwriters are instrumental to DRC’s mission and include:

 

Leading Sponsors

 

Sustaining Supporters

 

Event Sponsors

 

DRC Senior Director of Development Casey Davis said, “I can’t express enough the importance of our sponsors, and corporate and public underwriters to our mission to eradicate T1D through research. That’s what we mean when we say, ‘It takes a community to connect for a cure’.”

Through their help and that of family foundations and other donors, DRC expects to raise a record $750,000 in 2021, and anticipates it will increase that figure to $1 million in 2022.

“DRC is funding important research to find ways to prevent, better treat, and cure T1D. Donors and partners can also choose specific research projects they want to support. This enables you to see your dollars at work,” said Stephen Korniczky, DRC Board Member and Partner, Sheppard Mullin. “DRC not only supports a noble mission, they have been a wonderful partner as well.  I invite other sponsors and donors to join us in supporting DRC in 2022.”

DRC has additional sponsorships available for 2022 at a variety of levels. In honor of its 10-year anniversary it will be re-launching its annual Dance for Diabetes, and event sponsorships, in Fall 2022. Contact Casey Davis cdavis@diabetesresearchconnection.org.

To donate to DRC and double your impact with a tax-deductible donation click here by December 31, 2021.

Learn More +

Imagine: A World without Type 1 Diabetes

By 2050, 5 million people in the US are expected to be diagnosed with T1D; 600,000 of them will be children, requiring them to regularly monitor blood sugar and putting them at a higher risk for cardiovascular disease, kidney damage, blindness and other complications. Hear 18-year-old Cooper Buchanan describe how he learned he has T1D, and, how he and others are imagining a world where no one has to ever hear: You have T1D.

Learn More +

A Cure for Type 1 Diabetes? For One Man, It Seems to Have Worked

Commentary

Authors:

Vincenzo Cirulli, M.D., Ph.D.

Scientific Director, Diabetes Research Connection

Department of Medicine, UW Diabetes Institute

University of Washington

Institute for Stem Cells and Regenerative Medicine

 

Alberto Hayek, M.D.

Medical Director, Scripps/Whittier Diabetes Institute

Co-Founder, Diabetes Research Connection

 

David Winkler

Co-founder, past Chair and current CFO, Diabetes Research Connection

Past Chair, Scripps Whittier Diabetes Institute

Past Chair, American Diabetes Association, San Diego Chapter

Type 1 Diabetes Patient for 62 years  

 

A Cure for Type 1 Diabetes? For One Man, It Seems to Have Worked.

This article, which appeared in the New York Times (NYT) on Saturday, November 27, 2021, provides a promise for achieving a cure for type 1 diabetes (T1D). Dr. Melton, a brilliant scientist at Harvard, and an inspired father of two T1D patients is credited with overseeing this important effort which built on many past and present researchers’ discoveries.

While we applaud Dr. Melton and his team’s efforts for taking the necessary steps to bring this research to the bed-side, there are some questions that will need to be addressed. It remains to be determined if any issue or side effects will arise over time in some of the 17 patients participating to this initial clinical trial. Patient immunosuppression may be problematic, as it has been the case for some recipients of cadaveric human islet transplants. The long-term survival and function of these stem cell-derived beta cells will also need to be assessed, and design plans to replace them with additional transplants should they fail. Ultimately, the cost of the procedure and required FDA approval will also need to be addressed.

In the year 2000, the New England Journal of Medicine published an article that caused many to believe a cure for T1D had been discovered. The principal investigator, Dr. James Shapiro, initiated what became known as the Edmonton Protocol. This multicenter trial involved transplanting human cadaveric islets. Some issues soon arose: 1) an insufficient supply of islets; 2) failure of the islet transplants to function long-term; 3) complications associated with the site of transplantation into the portal vein of the liver, and 4) side effects caused by the immunosuppression of the recipients.

Undoubtedly, the most significant development since 2000 has been the conversion of pluripotent stem cells into insulin-producing cells to provide an unlimited supply of islet tissue for transplantation in T1D patients.

The need for immunosuppressive drugs to prevent rejection of the islet transplants remains an ongoing concern, although these types of drugs, and their regimen protocols have improved considerably since 2000. Notwithstanding, immunosuppression continues to have issues. Better drugs will be needed to ensure that the transplanted islet tissue is not rejected, retains its insulin-producing function over time, and that the recipients’ immune systems is not negatively impacted for its important primary function of fighting off other diseases.

Another approach to avoid rejection of pluripotent stem cell-derived beta cells is to encapsulate them. However, to date, these cells have not prospered in such enclosed environments, because current cell encapsulation technologies do not allow for these beta cells to intimately interact with blood vessels of the host to receive nutrients and oxygen to survive long term while performing their insulin secretory function in response to circulating glucose levels.

In two recent studies just published in peer-reviewed journals (https://www.cell.com/cell-stem-cell/fulltext/S1934-5909(21)00415-X), Canadian investigators led by Dr. Timothy Kieffer in collaboration with ViaCyte, and by ViaCyte scientists in collaboration with Dr. James Shapiro (https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(21)00338-4) reported that transplantation of immature stem cell-derived pancreatic islet progenitors in 15 and 17 patients, respectively, produced negligeable, yet detectable levels of human C-peptide production in response to a meal after a year from the day of transplantation. These studies were conducted using devices that allow some level of interaction of the transplanted cells with the patient’s blood vessels, thus requiring immune suppression. The bottom line is that after ~1 year, none of the patients became independent from insulin injections and all required exogenous insulin during the trial.

A possible solution to the problem of allorejection (i.e., immune rejection of “non-self” cells, coming from a different genetic background) may involve the use of a T1D patient’s own cells to generate induced pluripotent stem cells (or iPS), produced through a technique of reprogramming, and then convert these iPS cells into pancreatic beta cells. These “self-cells” may evade rejection by mechanisms of allo-immunity; however, auto-reactive immune cells that caused T1D in the first place in these patients may still target and destroy these newly transplanted beta cells.

San Diego’s ViaCyte is pursuing another potential cure. This company recently announced a collaboration with Crisper, a biotech leader in DNA editing to genetically modify the stem cells to avoid the need for immune therapy post-transplantation.

Ultimately, in order to ensure that all of the above treatments are safe for transplantation in the general population of T1D patients the FDA will require: 1) a careful peer-reviewed analysis of the results on all patients; 2) a long-term assessment of the survival and function of the transplanted cells; 3) evaluation of the long-term effects of immunosuppression; and 4) determination of the acceptability of all side effects.

Collectively, what all of these recent advancements show is that there is much more to be learned before stem cell derived islet tissue can be routinely and safely used for cell replacement therapy in T1D.

Hence, notwithstanding these open questions, substantial progress is being made towards a functional cure for T1D. We must proceed with hope and caution while pursuing additional innovative research.

The DRC is committed to continue supporting innovative basic and translational research by early-career scientists who strive to prevent, find better treatments for, and cure T1D.

 

Learn More +

We’re Committed to Eradicating T1D

Five million people are expected to have T1D by 2050 and 40,000 are diagnosed with T1D each year in the U.S. Our Executive Director Karen Hooper discussed DRC’s unique mission in raising research dollars for early-career scientists to develop innovative studies that will lead to the end of T1D. Learn about our commitment to not rest until T1D is eliminated in this recent Spotlight on the Community podcast.

Learn More +
Happy Holidays

DRC Wishes You A Happy Holiday!

Dear Supporter,

In consideration of the safety and comfort of our community, and the uncertainty for the effects of COVID-19 and its variant in indoor settings, DRC had to postpone events in 2021.

However, we are thrilled to announce we will be honoring our 10-year anniversary by throwing an epic party for our Dance for Diabetes in 2022. Stay tuned for more details.

Thank you for your continued support and partnership!

 

Happy Holidays, 

The DRC Team

Learn More +

Diabetes Research Connection Awards $400,000 to Eight Promising T1D Studies as Nation Observes National Diabetes Month

After rigorous review by DRC’s Scientific Review Committee, eight early-career researchers receive seed funding for their work to find the cause, treatment, and cure for T1D

November 08, 2021 04:25 PM Eastern Standard Time

SAN DIEGO–(BUSINESS WIRE)–Diabetes Research Connection (DRC), a 501(c)(3) that funds research projects conducted by early-career researchers aimed at prevention, cure, and better care for those with Type 1 Diabetes (T1D), puts out a call for T1D research in need of seed funding twice a year. After a rigorous review by the DRC Scientific Review Committee (SRC), comprised of T1D experts nationwide, the most promising studies are selected to receive seed funding. The first round of grants for 2021 was recently completed as the nation observes National Diabetes Month. Funds were provided to seven researchers (with an additional study pending contract approvals) totaling a $400,000 investment. Researchers receiving grants include:

“The DRC has filled a niche by providing seed funding to the most promising T1D research being conducted by innovative early-career scientists”

  • Dr. Michael Kalwat – Indiana Biosciences Research Institute
  • Dr. Sudpita Ashe – University California, San Francisco
  • Dr. Balamurugan Dhayalan – Indiana University
  • Dr. Yao Wang – University of California, San Francisco
  • Dr. Yi Wang – University of California, San Francisco
  • Dr. Flavia Pechanha – University of Miami
  • Dr. Madhumita Basu – Nationwide Children’s Hospital
  • Additional study pending contract approvals

Those selected are conducting a variety of T1D studies, ranging from the role of TSA genes in T1D, to preventing and possibly curing T1D by blocking the autoimmune attack of beta cells. Individuals can view the full summary of projects and donate to the research study of their choice.

Alberto Hayek, M.D., a renowned diabetes expert, former Scientific Director at San Diego’s Scripps Whittier Institute for Diabetes, Professor Emeritus of Pediatrics at UCSD, and DRC board member, notes how far diabetes research has come since the 1960s. Back then, diabetes in children was often viewed as fatal.

Today, continuous glucose monitoring and loop systems automatically sense how much insulin to inject. However, there is still no known cure to the autoimmune disease which 1.6 million Americans are living with today. View DRC’s “Imagine a World Without T1D” video.

“The DRC has filled a niche by providing seed funding to the most promising T1D research being conducted by innovative early-career scientists,” says Hayek. “From graduate students to junior assistant professors – they all have the ability to compete for funding with DRC – even for ‘high risk’ grants, often overlooked by others, that have potential to forever change views or research on T1D.”

To apply for funding, researchers first submit an LOI to be reviewed by DRC’s SRC. If approved, the applicant is invited to submit a grant application. U.S.-based post-doctoral fellows, professors, and instructors whose research is focused on T1D and have not received NIH funding as a Principal Investigator, are eligible to apply. Once a study has been approved by DRC, donors have the opportunity to support a research project of their choice and interact with the researchers themselves via the DRC website.

Learn More +
T1D

Imagine: A World Without Type 1 Diabetes

As we begin to reflect on all that has happened in the world over the past 18+ months, it is even more incredible to share the progress that the Diabetes Research Connection (DRC) has made. Despite the global pandemic, despite the decline in donations, and despite the fact we have been unable to be together in person, we are fighting to end Type 1 Diabetes more than ever before. 

We must end this disease, and to do that, we need to all commit to finding the best and brightest early-career scientists in the nation and provide seed funding for their promising research. We must invest in novel ideas, with the most promise, to ensure a future where nobody has to hear “You have Type 1 Diabetes.” 

Click HERE to view the full November Newsletter!

Learn More +
DRC and Rainman's Take

DRC’s President and Chair and the Senior Director of Development Speak on the Podcast Rainman’s Take

In late September, DRC’s President and Chair, C.C. King, and the Senior Director of Development, Casey Davis, spoke on the Podcast Rainman’s Take. This podcast is hosted by Brian, the “Rainman” Lukacz. He speaks on a variety of topics and gives his take on them.

During this 1+ hour episode, Rainman talks with C.C. and Casey about their innovative approach to charitable giving in the fight for a cure for type 1 diabetes. DRC’s process allows donors to have a direct connection with the research they are funding that maintains transparency and is an incredibly efficient use of donated funds.

Click HERE to view the podcast.

Learn More +
Protecting Beta Cells

Protecting Pancreatic Beta Cells During Cell Transplantation

One of the hallmarks of type 1 diabetes (T1D) is the destruction of insulin-producing pancreatic beta cells. The immune system mistakenly attacks these cells leaving the body unable to regulate blood glucose levels naturally. Instead, insulin must be administered manually or via an insulin pump in order to prevent hyperglycemia.

Researchers have been experimenting with cell transplantation methods to replace these depleted cells and enable the body to produce its own insulin once again. A major obstacle to this approach is cell survival and viability. The stress of injecting the cells can cause cell death, and the body often treats the transplanted cells as foreign bodies and elicits an immune response to destroy them. Scientists have used various strategies for encapsulating the cells to reduce stress and protect them from the immune system. Some have been more effective than others.

new study examines the effectiveness of caging pancreatic islets in a multilayer hydrogel nanofilm. The nanofilm combines monophenol-modified glycol chitosan and hyaluronic acid to create a thin protective barrier that still enables oxygen and nutrients to flow into the caged cells while also allowing insulin and waste to flow out. In addition, it provides immunoisolation, eliminating the need for immunosuppressants.

When tested in T1D-induced mouse models, the nanofilm-caged spheroids were able to achieve normoglycemia compared to control groups. Scientists further evaluated their effectiveness by removing the kidney where the spheroids had been transplanted. As a result, the mice experienced hyperglycemia once again. Using a multilayer hydrogel nanofilm provided protection against mechanical stress and immune response while enabling the islets to regulate blood glucose levels.

Although this approach has only been tested on mouse models thus far, it provides a new approach for cell-based therapies. More research and testing are needed to determine if this transplantation method triggers the same effects in humans. It could one day open the door to new treatment options for individuals with type 1 diabetes.

Though not involved in this study, the Diabetes Research Connection (DRC) is committed to furthering research around T1D to improve diagnosis, treatment, and management of the disease and find a cure one day. The organization provides critical funding to early-career scientists pursuing novel research studies on T1D. Learn more and support current projects by visiting https://diabetesresearchconnection.org

Please DONATE NOW so DRC can keep bringing you credible, peer-reviewed T1D news and research.

Thank you.

Learn More +
Dana Levin

Getting to know Fellow T1D – Dana Levin at Centura Wealth Advisory

Diabetes has taught me throughout my life to always have a backup plan for the backup plan. From the early days in 1994 when I was first diagnosed with T1D, my doctors always recommended keeping a snack and glucose tablets with me in case my blood sugars dipped low. To this day, my purse is always loaded with granola bars, nuts, and candy – it’s like a compact mini-mart. And it comes in handy often when restaurants take longer to bring the food than expected, and I’ve already bolused, or I find myself walking further on the beach than anticipated, and I feel my body starting to shake. When I travel, especially internationally, I make sure to keep a loaner insulin pump with me as well as pump and CGM supplies stashed in multiple suitcases and syringes with back up forms of insulin in case something crazy happens – and crazy, unexpected things always happen while traveling (it’s part of the adventure) and so long as I have my backups in place, my diabetes doesn’t have to control my life or plans.

As a newly diagnosed T1D at the age of 12, I never could have imagined how diabetes would impact the course of my career. Philanthropy has always been an essential part of my life, and giving back to the community was modeled for me at home by my parents, who were both educators in the public school system. My parents encouraged me to participate in many Walks for Diabetes and as part of the event, to send fundraising letters to friends and family. This annual exercise and leadership opportunity, coupled with many other volunteer experiences, guided me towards a career focused on philanthropy and giving back to the community. For 16 years, I worked as a fundraiser in a variety of nonprofit organizations, including one in the T1D space. I loved this work, and it has guided me to my current role at Centura Wealth Advisory as the Director of Philanthropic Strategies.

For the past year, I have been partnering with families to ensure that they have financial and philanthropic plans in place for their estate – both short and long-term. Together, we walk through conversations about their legacy and dreams as they plan for the future. The global pandemic of this past year has caused many families to either put living wills and trusts in place with a financial planner and estate attorney or to brush off older documents to ensure their intentions are still accurate. For those who have not done this yet, it is a highly recommended practice, so when life happens, financial decisions don’t need to be added to already stressful situations, medical or otherwise. This is having your backup plan in place, so to speak.

As someone with T1D, I never thought I would qualify for life insurance, one key component of an ultimate backup plan. I was concerned that if something happened to me, would my husband be able to pay our mortgage and take care of our family? Thankfully, a small handful of life insurance carriers will offer life insurance to people who live with T1D. Getting this coverage has provided me relief and comfort as well as filled a gap in my estate plan. With an A1c of 6.3, which I work on every single day, I focus on keeping myself as healthy and complication-free as possible; however, I know that as life changes, I can sleep better (despite my Dexcom beeping at me) because I have this coverage. In addition to partnering and supporting families at Centura as they build their estate plans, I am confident that my personal backup plan is also in place to provide for my family. I encourage everyone to have conversations with the trusted financial services professionals in your lives to ensure you have your plans in place so that you can live a more peaceful life.

Dana began working at Centura Wealth Advisory in 2020 as the Client Relationship Manager. She joined the team to bring together her passion for philanthropy with her commitment to help families build wealth and give back to the community. 

Learn More +

Unlimited access to all the essential project updates latest diabetes research news, and more.